LNTHNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

Lantheus Holdings, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$99.92+0.22 (+0.22%)

Close on Oct 19, 2026

Market cap: $6.75B
P/E (TTM): 24.2
Dividend yield: –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Total debt

$571.05M

$697.00K due within a year

Net debt

-$22.25M

After $593.30M of cash

Implied interest rate

3.48%

FY2025 interest ÷ average debt

Interest coverage

15.7×

FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Lantheus's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Lantheus's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is LNTH.

Revenue growth2.3% · median -1.4%

Gross margin60.1% · median 54.9%

Operating margin19.4% · median -6.5%

Net margin17.7% · median -10.2%

Company	Revenue	Growth
IDXX	$4.55B	+12.8%
QDEL	$2.67B	-2.5%
LNTH	$1.56B	+2.3%
NEOG	$883.99M	-0.3%
MYGN	$806.60M	-3.2%
TLX	–	–

Company

Next earnings (est.): Nov 5, 2026, before open
Exchange: Nasdaq
Industry: In Vitro & In Vivo Diagnostic Substances
Fiscal year ends: December 31
Employees: 1,193
Held by institutions: 100.0%
Auditor: Deloitte & Touche LLP
SEC CIK: 1521036

Advertisement
300 × 250